Search research articles
Contact Us
Filters
Showing results (91-100 of 131) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
Anastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Clinical Pharmacokinetics
|
November 18, 2025
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
Marian Klose, Ilaria Colombo, Katrin Gobat, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
Cancers
|
May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Blood Advances
|
October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 131) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
Anastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
The Lancet. Oncology
|
May 14, 2021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, et al.
Clinical Pharmacokinetics
|
November 18, 2025
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
Marian Klose, Ilaria Colombo, Katrin Gobat, et al.
Blood Advances
|
July 5, 2022
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Juan P Alderuccio, Weiyun Z Ai, John Radford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Philippe L Bedard, Josep Tabernero, Filip Janku, et al.
Cancers
|
May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Blood Advances
|
October 23, 2023
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Page
of 14